RecruitingPhase 2

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

United States90 participantsStarted 2025-06-27

Plain-language summary

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

To assess the efficacy of TYRA-300 in LG IR-NMIBC participants

Timeframe: at 3 months

NCT IDNCT06995677

SponsorTyra Biosciences, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-02

Grace Indyk